Triple Negative Breast Cancer (TNBC)
The Department of Clinical Oncology at the Narodowy Instytut Onkologii is conducting studies that assess new immunotherapy approaches for triple‑negative breast cancer. Trials focus on measuring complete tumor disappearance after surgery and tracking survival without disease recurrence.
- Pathologic complete response evaluation
- Event‑free survival analysis
- Neoadjuvant and adjuvant immunotherapy
- Combination of checkpoint inhibitor with chemotherapy
Patients benefit from cutting‑edge treatment options while researchers gather data to improve long‑term outcomes.
Renal Cell Carcinoma
Investigators are testing the effectiveness of a checkpoint inhibitor as a single‑agent adjuvant therapy after surgical removal of the kidney. The study aims to determine whether this approach can extend overall survival for patients with renal cell carcinoma.
- Adjuvant therapy after nephrectomy
- Overall survival measurement
- Safety and tolerability assessment
- Long‑term disease‑free monitoring
The research supports the institute’s commitment to advancing care for patients with advanced kidney cancers.
Advanced Tumor Research
Across multiple solid tumor types, the clinic evaluates novel immunotherapeutic agents to improve response rates and survival. Studies include patients with advanced tumors and assess disease‑free and overall outcomes.
- Evaluation of disease‑free survival
- Overall survival endpoints
- Biomarker-driven patient selection
- Safety profiling of emerging treatments
The site’s multidisciplinary team collaborates to bring innovative therapies from bench to bedside.
